Equities research analysts expect that AC Immune SA (NASDAQ:ACIU) will announce earnings of ($0.30) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for AC Immune’s earnings, with the lowest EPS estimate coming in at ($0.33) and the highest estimate coming in at ($0.27). AC Immune posted earnings per share of ($0.28) during the same quarter last year, which indicates a negative year over year growth rate of 7.1%. The firm is expected to issue its next quarterly earnings report on Friday, November 12th.
According to Zacks, analysts expect that AC Immune will report full year earnings of ($0.72) per share for the current fiscal year, with EPS estimates ranging from ($1.20) to $0.11. For the next fiscal year, analysts expect that the business will post earnings of ($0.25) per share, with EPS estimates ranging from ($1.07) to $0.22. Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for AC Immune.
AC Immune (NASDAQ:ACIU) last posted its quarterly earnings results on Tuesday, August 3rd. The company reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.02). AC Immune had a negative return on equity of 35.48% and a negative net margin of 405.01%.
Shares of NASDAQ:ACIU traded down $0.03 during trading on Monday, hitting $6.33. 2,298 shares of the company were exchanged, compared to its average volume of 1,117,631. The stock has a market cap of $459.89 million, a price-to-earnings ratio of -5.68 and a beta of 0.79. AC Immune has a fifty-two week low of $4.42 and a fifty-two week high of $12.61. The firm has a fifty day moving average price of $6.84 and a two-hundred day moving average price of $7.02.
Several hedge funds have recently bought and sold shares of the stock. EcoR1 Capital LLC boosted its stake in AC Immune by 51.4% in the 1st quarter. EcoR1 Capital LLC now owns 3,648,163 shares of the company’s stock valued at $27,763,000 after purchasing an additional 1,237,923 shares during the period. BVF Inc. IL lifted its position in shares of AC Immune by 13.9% during the 2nd quarter. BVF Inc. IL now owns 8,545,179 shares of the company’s stock valued at $67,763,000 after acquiring an additional 1,040,600 shares during the period. Point72 Asset Management L.P. bought a new stake in shares of AC Immune during the 2nd quarter valued at $2,986,000. Balyasny Asset Management LLC lifted its position in shares of AC Immune by 901.1% during the 2nd quarter. Balyasny Asset Management LLC now owns 260,856 shares of the company’s stock valued at $2,069,000 after acquiring an additional 234,798 shares during the period. Finally, Millennium Management LLC lifted its position in shares of AC Immune by 1,092.2% during the 1st quarter. Millennium Management LLC now owns 252,026 shares of the company’s stock valued at $1,918,000 after acquiring an additional 230,886 shares during the period. 25.04% of the stock is currently owned by institutional investors and hedge funds.
About AC Immune
AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.
Featured Story: Debt-To-Equity Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.